Lipids and lipoproteins modulate the expression and/or function of thrombotic, fibrinolytic and rheological factors. Many studies have suggested a link between risk factors for venous thromboembolism (VTE), and dyslipidemia but results are heterogeneous. We sought to identify witch dyslipidemia profil is more associated with VTE disease.

We have developed a case control study including 32 patients wiyh experience of VTE and 33 controls matched in age and sex. We proceeded to compare the lipidique profile of the two groups after dosing the total cholesterol, triglycerides, cHDL, and cLDL, Lipoprotein Lpa, ApoA, ApoB and ApoE. Patients with experience of cancer and whos taken statin or fibrat are excluded.

The two groups have the same demographic characteristics and there was more diabetics and fatty patients in the VTE group than control; 37% vs18% and IMC>30Kg/m² in 43.8 vs 18.2. The median value of total cholesterol, the cLDL, Lipoprotein Lpa, and ApoB are Higher in the VTE group (4.942±1.409, 4.362±0.872) P=0.049, LDL-c, (3.114±1.100; vs 2.247±0.0.880) P=0.001. Lpa (0.205±0. 115; vs 0.0819±0.0479, P 10-3). ApoB (1.3338±02536; vs 08006±02388) P=0.001. In opposite the mean value of cHDL and lipoprotein Apo A1 was lower in the VTE group; cHDL (1.048±0.237, 1.473±0.334) P<0.001, A poA1 (1.010±0.2437; vs 1.414±0.2911). There was 21 patients (65.6%) in the VTE group vs 4 patients (12.1%) with a cHDL<0.906mmol/l, P<0.001. OR; 2 CI [0.749-5.038] and 18 patients (75%) with adiopathique thrombosis OR: 5 CI [0.910-27.470].

Our study confirmed that VTE is more frequent in the patient with low cHDL and ApoA1 and higher cLDL, ApoB and Lpa. This result must be confirmed with a large population study.